TriVascular
Santa Rosa
About TriVascular
TRIVASCULAR is committed to developing new medical devices that address unmet clinical needs while providing an excellent working environment for its employees. The company was founded by Michael Chobotov, Ph.D., Robert Whirley, Ph.D., and Joseph Humphrey, Ph.D. TriVascular is located 50 miles north of San Francisco in the heart of the Sonoma Wine Country. TriVascular offers excellent career opportunities, benefits and quality of life to its employees. TRIVASCULAR's first products are next-generation transluminally placed endovascular grafts, often referred to as stent-grafts, for the treatment of aneurysmal disease in the abdominal aorta (AAA) and the thoracic aorta (TAA). Such endovascular procedures can lead to substantially lower mortality, morbidity, and cost compared to open surgical repair. TriVascular has developed a novel device design that achieves a low profile, permitting substantially improved access through the vasculature.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 251 – 500
- Estimated revenue: $10K – $50K
- Total funding: $413.0M
- Funding stage: M&A
- Last round: Post-IPO Debt (Aug 2015)
- Ticker: nasdaq:TRIV
- Website: trivascular.com
- Phone: 800 983 2284
Industries & Categories
Health Care, Health Diagnostics, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/trivascular-2898687 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.